Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.6% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 4.6% during trading on Monday . The stock traded as low as $8.62 and last traded at $8.85. Approximately 15,164,269 shares changed hands during trading, a decline of 41% from the average daily volume of 25,553,969 shares. The stock had previously closed at $9.28.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th.

Recursion Pharmaceuticals Stock Down 3.5 %

The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of -5.81 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business’s 50 day moving average is $7.56 and its 200 day moving average is $7.03.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc lifted its position in Recursion Pharmaceuticals by 0.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after acquiring an additional 1,300 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the period. Axxcess Wealth Management LLC boosted its position in Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after buying an additional 1,795 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock worth $176,000 after buying an additional 1,875 shares during the period. Finally, Wedmont Private Capital raised its position in Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.